-
War's impact on fertilisers stirs food producer fears
-
US inflation surges to 3.3% as Iran war impact bites
-
Thais fete new year with family despite fuel price spike
-
Scheffler scrambles, Rose stumbles early at Masters
-
On Iran truce, all sides want bigger China role, but does China?
-
Sinner eases into Monte Carlo semi-final against Zverev
-
Inter skipper Martinez suffers calf injury
-
Ukrainians sceptical as Kremlin orders Easter truce
-
Arteta urges Arsenal to pile pressure on Man City in title race
-
Pay fears grow for US security workers in shutdown
-
Hungary rivals rally crowds in closing strait of election campaign
-
Swede goes on trial for pressuring wife to sell sex
-
US inflation surges 3.3% as Iran war impact bites
-
Vance warns Iran not to 'play' US at talks in Pakistan
-
Fernandez remains out despite apology: Chelsea boss Rosenior
-
Dortmund defender Schlotterbeck extends contract until 2031
-
De Zerbi vows to save troubled Spurs from relegation
-
Antwerp port reopens to North Sea shipping after oil spill
-
Stocks mixed, oil steadies on guarded optimism for Iran ceasefire
-
Sinner eases into Monte Carlo semi-finals
-
France's Macron talks war, peace and basketball with Pope Leo
-
Fernandez apologised over comments about his future: Chelsea's Rosenior
-
Coach Spalletti signs new Juve deal until 2028
-
AI chatbots offer children harm as if it were help, says activist
-
'Grumpy' Guardiola wants Silva to stay at Man City for life
-
Zverev beats Fonseca to reach Monte Carlo semi-finals
-
Scheffler, Rose to chase McIlroy with early Masters starts
-
Celine Dion's Paris concerts promise to spin the money on and on
-
Stocks climb, oil steadies on guarded optimism over Iran war ceasefire
-
Irish govt to meet farmers, hauliers over fuel cost fears
-
Injured Bayern starlet Karl to miss Real return leg
-
US-Iran talks in Pakistan uncertain as sides trade accusations
-
Oil spill snarls shipping traffic in Antwerp port
-
Giving birth in a shelter in Israel
-
Five things to know about the planned Iran-US talks in Islamabad
-
Slot feels 'complete support' from Liverpool chiefs despite slump
-
Kyiv books tentative diplomatic coup with Iran war forays
-
Teenager shines as Britain seize control of BJK Cup tie with Australia
-
Chinese, Taiwanese will unite, Xi tells Taiwan opposition leader
-
Sleepy seal diverts traffic in Australian seaside town
-
Artemis astronauts to shed light on space health risks
-
Pakistan prepares to host US-Iran talks, as Lebanon fighting continues
-
Vaccine gaps fuel Bangladesh's deadly measles crisis
-
Fish furore fuels fierce election in India's West Bengal
-
Coachella kicks off with headliners Sabrina Carpenter, Bieber and Karol G
-
Myanmar junta chief sworn in as president
-
Exiled cartoonists give voice to Iran's silenced millions
-
In Pakistan's mediation to end Mideast war, China may hold the key
-
Knicks stay in hunt with late win over rival Celtics
-
'Sartorial diplomacy' on show in expo of late UK queen's fashion
Ainos to Participate in Fireside Chat with Water Tower Research on August 20, 2025
SAN DIEGO, CALIFORNIA / ACCESS Newswire / August 11, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a pioneer in AI-powered scent detection, today announced that it will participate in a fireside chat with Robert Sassoon, senior research analyst at Water Tower Research, on Wednesday, August 20, 2025, at 11:00 a.m. ET.
Ainos will highlight the uniqueness of its AI Nose technology, underscoring recent strategic partnerships and the rapid acceleration of AI Nose deployment. In addition, the Company will also share insights into market and scale-up opportunities across multiple sectors, outline key milestones expected for the remainder of 2025 and into 2026, and make the case for why Ainos should be regarded as a technology company at its core.
To register for this listen-only event, please visit:
Fireside Chat Registration Link
The replay of the fireside chat will be available under "Events" on Ainos' investor relations website at https://ir.ainos.com/.
About AI Nose
AI Nose digitizes scent into Smell ID, an AI-driven scent intelligence. This full-stack electronic nose (e-nose) platform combines precision MEMS sensor arrays with proprietary AI algorithms, aiming to detect scent at parts-per-billion (ppb) sensitivity. Smell ID then converts analog scent data into actionable insights, while the proprietary smell language model (SLM) learns complex scent patterns. Backed by a 13-year scent data moat and deep medtech expertise, AI Nose aims to deliver continuous monitoring, predictive analytics, and instant alerts to boost safety, quality, and efficiency. To be delivered as SmellTech-as-a-Service, it aims to offer subscription access to ongoing scent intelligence, analytics, and real-time alerts, turning the invisible into strategic advantage.
About Ainos, Inc.
Ainos, Inc. (NASDAQ:AIMD) is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos, a fusion of "AI" and "Nose," is redefining machine perception for the sensory age. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.
Contact Information:
Feifei Shen
[email protected]
SOURCE: Ainos, Inc.
View the original press release on ACCESS Newswire
F.Wilson--AT